Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis

References

• Stat Fact Sheets SEFemale breast cancer2017 Available from: seer.cancer.gov/statfacts/html/Breast/Assessed January 16, 2018
   Google Scholar
• CardosoFCostaANortonLESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)Ann Oncol201425101871188825234545
   PubMed Web of Science ®Google Scholar
• MigliaccioIMalorniLHartCDGuarducciCDi LeoAEndocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersBMC Med2015134625857348
   PubMed Web of Science ®Google Scholar
• JoyAAGhoshMFernandesRClemonsMJSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesCurr Oncol201522Suppl 1S29S4225848337
   PubMedGoogle Scholar
• FanWChangJFuPEndocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategiesFuture Med Chem20157121511151926306654
   PubMed Web of Science ®Google Scholar
• XuHBLiuYJLiLAromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysisClin Breast Cancer201111424625121737354
   PubMed Web of Science ®Google Scholar
• HowellARobertsonJFQuaresma AlbanoJFulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentJ Clin Oncol200220163396340312177099
   PubMed Web of Science ®Google Scholar
• OsborneCKPippenJJonesSEDouble-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trialJ Clin Oncol200220163386339512177098
   PubMed Web of Science ®Google Scholar
• HowellARobertsonJFAbramPComparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trialJ Clin Oncol20042291605161315117982
   PubMed Web of Science ®Google Scholar
• ChiaSGradisharWMauriacLDouble-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTJ Clin Oncol200826101664167018316794
   PubMed Web of Science ®Google Scholar
• di LeoAJerusalemGPetruzelkaLResults of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancerJ Clin Oncol201028304594460020855825
   PubMed Web of Science ®Google Scholar
• Di LeoAJerusalemGPetruzelkaLFinal overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trialJ Natl Cancer Inst20141061djt33724317176
   PubMedGoogle Scholar
• PritchardKIRolskiJPapaiZResults of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)Breast Cancer Res Treat2010123245346120632084
   PubMed Web of Science ®Google Scholar
• CopeSOuwensMJJansenJPSchmidPProgression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival modelsValue Health201316240341723538193
   PubMed Web of Science ®Google Scholar
• CristofanilliMTurnerNCBondarenkoIFulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialLancet Oncol201617442543926947331
   PubMed Web of Science ®Google Scholar
• WalkerAJWedamSAmiri-KordestaniLFDA approval of pal-bociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancerClin Cancer Res201622204968497227407089
   PubMed Web of Science ®Google Scholar
• AyyagariRTangDPatterson-LombaOProgression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysisCurr Med Res Opin20183491645165229781326
   PubMed Web of Science ®Google Scholar
• HuttonBSalantiGCaldwellDMThe PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanationsAnn Intern Med20151621177778426030634
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGotzschePCCochrane Bias Methods Group; Cochrane Statistical Methods GroupThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• ZhouZRZhangTSLiBExtracting and transforming of appropriate data of meta-analysis in survival curveChin J Evid Based Cardiovasc Med20146243247
   Google Scholar
• WeltonNJSuttonAJCooperNJAbramsKRAdesAEEvidence synthesis for decision making in healthcareChichester (UK)John Wiley & Sons, Inc2012
   Google Scholar
• SlamonDJNevenPChiaSPhase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONA-LEESA-3J Clin Oncol201836242465247229860922
   PubMed Web of Science ®Google Scholar
• SledgeGWJrToiMNevenPMONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2–advanced breast cancer who had progressed while receiving endocrine therapyJ Clin Oncol201735252875288428580882
   PubMed Web of Science ®Google Scholar
• Di LeoAJohnstonSLeeKSBuparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol20181918710029223745
   PubMed Web of Science ®Google Scholar
• BaselgaJImSAIwataHBuparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201718790491628576675
   PubMed Web of Science ®Google Scholar
• ZamanKWinterhalderRMamotCFulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08Eur J Cancer201551101212122025892646
   PubMed Web of Science ®Google Scholar
• MusolinoACamponeMNevenPPhase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2– breast cancer that had progressed during or after prior endocrine therapyBreast Cancer Res20171911828183331
   PubMedGoogle Scholar
• KropIEMayerIAGanjuVPictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trialLancet Oncol201617681182127155741
   PubMed Web of Science ®Google Scholar
• ClemonsMJCochraneBPondGRRandomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyBreast Cancer Res Treat2014146115316224924416
   PubMed Web of Science ®Google Scholar
• AdelsonKRamaswamyBSparanoJARandomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialNPJ Breast Cancer201621603728721390
   PubMedGoogle Scholar
• KornblumNZhaoFManolaJRandomized Phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102J Clin Oncol201836161556156329664714
   PubMed Web of Science ®Google Scholar
• WilsonSChiaSKTreatment algorithms for hormone receptor-positive advanced breast cancer: applying the results from recent clinical trials into daily practice-insights, limitations, and moving forwardAm Soc Clin Oncol Educ Book201333e20e27
   Google Scholar
• KwapiszDCyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclibBreast Cancer Res Treat20171661415428741274
   PubMed Web of Science ®Google Scholar
• ButtAJMcNeilCMMusgroveEASutherlandRLDownstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin EEndocr Relat Cancer200512Suppl 1S47S5916113099
   PubMed Web of Science ®Google Scholar
• FinnRSDeringJConklinDPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res2009115R7719874578
   PubMed Web of Science ®Google Scholar
• ChirilaCMitraDColosiaAComparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysisJ Cell Biochem201733814571466
   Google Scholar
• WilsonFRVaruAMitraDCameronCIyerSSystematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancerBreast Cancer Res Treat2017166116717728752187
   PubMed Web of Science ®Google Scholar
• Lopes de MenezesDEPengJGarrettENCHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemiaClin Cancer Res200511145281529116033847
   PubMed Web of Science ®Google Scholar
• HeinzleCSutterlütyHGruschMGrasl-KrauppBBergerWMarianBTargeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapyExpert Opin Ther Targets201115782984621375471
   PubMed Web of Science ®Google Scholar
• EastonDFPooleyKADunningAMGenome-wide association study identifies novel breast cancer susceptibility lociNature200744771481087109317529967
   PubMed Web of Science ®Google Scholar
• Ruiz-NarváezEAHaddadSALunettaKLGene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortiumBreast Cancer Res Treat2016155235536326743380
   PubMed Web of Science ®Google Scholar
• AndréFCortésJRationale for targeting fibroblast growth factor receptor signaling in breast cancerBreast Cancer Res Treat201515011825677745
   PubMed Web of Science ®Google Scholar
• RugoHVidulaNMaCImproving response to hormone therapy in breast cancer: new targets, new therapeutic optionsAm Soc Clin Oncol Educ Book201635e40e5427249746
   PubMedGoogle Scholar
• AndréFBachelotTCamponeMTargeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancerClin Cancer Res201319133693370223658459
   PubMed Web of Science ®Google Scholar
• LinWZXuQNWangHBLiXYFulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trialsBreast Cancer201724334535228324247
   PubMed Web of Science ®Google Scholar